About: Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests
Creator	Chevereau-Choquet, Marie Colin, Mathilda Courtellemont, Laura Giachè, Susanna Gubavu, Camélia Guinard, Jérôme Hocqueloux, Laurent Kiani, Catherine Pialoux, Gilles Prazuck, Thierry Rodot, Victor Rzepecki, Vincent Seve, Aymeric
source	MedRxiv
abstract	Background The SARS-CoV-2 virus is responsible for the infectious respiratory disease called COVID-19 (COronaVIrus Disease). In response to the growing COVID-19 pandemic, Rapid Diagnostic Tests (RDTs) have been developed to detect specific antibodies, IgG and IgM, to SARS-CoV-2 virus in human whole blood. We conducted a real-life study to evaluate the performance of two RDTs, COVID-PRESTO and COVID-DUO, compared to the gold standard, RT-PCR. Methods RT-PCR testing of SARS-Cov-2 was performed from nasopharyngeal swab specimens collected in adult patients visiting the infectious disease department at the hospital (Orleans, France). Fingertip whole blood samples taken at different time points after onset of the disease were tested with RDTs. The specificity and sensitivity of the rapid test kits compared to test of reference (RT-PCR) were calculated. Results Among 381 patients with symptoms of COVID-19 who went to the hospital for a diagnostic, 143 patients were RT-PCR negative. Results of test with RDTs were all negative for these patients, indicating a specificity of 100% for both RDTs. In the RT-PCR positive subgroup (n=238), 133 patients were tested with COVID-PRESTO and 129 patients were tested with COVID-DUO (24 patients tested with both). The further the onset of symptoms was from the date of collection, the greater the sensitivity. The sensitivity of COVID-PRESTO test ranged from 10.00% for patients having experienced their 1st symptoms from 0 to 5 days ago to 100% in patients where symptoms had occurred more than 15 days before the date of tests. For COVID-DUO test, the sensitivity ranged from 35.71% [0-5 days] to 100% (> 15 days). Conclusion COVID-PRESTO and DUO RDTs turned out to be very specific (none false positive) and to be sensitive enough after 15 days from onset of symptom. These easy to use IgG/IgM combined test kits are the first ones allowing a screening with capillary blood sample, by typing from a finger prick. These rapid tests are particularly interesting for screening in low resource settings.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1101/2020.05.27.20112888
has license	medrxiv
sha1sum (hex)	37cda5d8d37f0e8f060fd661274d2fb9df4dc145
schema:url	https://doi.org/10.1101/2020.05.27.20112888
resource representing a document's title	Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests
resource representing a document's body	covid:37cda5d8d37f0e8f060fd661274d2fb9df4dc145#body_text
is schema:about of	named entity 'Authors' named entity 'control line' named entity 'medRxiv' named entity 'preprint' named entity 'COVID' named entity 'antibodies' named entity 'peer review' named entity 'global health emergency' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'medRxiv' named entity 'vaccine' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'fatigue' named entity 'viral infection' named entity 'WHO' named entity 'respiratory failure' named entity 'MERS-CoV' named entity 'RT-PCR' named entity 'global outbreak' named entity 'preprint' named entity 'Nucleic acid' named entity 'IgM' named entity 'Health workers' named entity 'preprint' named entity 'antibody' named entity 'respiratory disease' named entity 'virus' named entity 'virus' named entity 'study population' named entity 'World Health Organization' named entity 'COVID-19' named entity 'IgG' named entity 'preprint' named entity 'viral infections' named entity 'serum' named entity 'COVID' named entity 'viruses' named entity 'RNA' named entity 'Antibody Tests' named entity 'IgG' named entity 'medRxiv' named entity 'humoral response' named entity 'pneumonia' named entity 'Middle East' named entity 'real-time RT-PCR' named entity 'Qiagen' named entity 'CC-BY-ND' named entity 'infection' named entity 'WHO' named entity 'recombinant' named entity 'blood samples' named entity 'SARS outbreak in 2003' named entity 'rapid tests' named entity 'preprint' named entity 'IgM' named entity 'capillary' named entity 'polyester' named entity 'immunoassay' named entity 'humoral response' named entity 'IgG' named entity 'incubation' named entity 'COVID' named entity 'control line' named entity 'medRxiv' named entity 'CC-BY-ND' named entity 'preprint' named entity 'COVID' named entity 'micropipette' named entity 'preprint' named entity 'IgG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software